Ventilator associated pneumonia in critically III patients: Prevention and treatment

Turkish Journal of Medical Sciences

Volumn 33, Issue 4, 2003, Pages 215-222

  Michalopoulos, Argyris ^a   Geroulanos, Stefanos ^a  

^a ONASSIS CARDIAC SURGERY CENTER   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMPICILLIN; ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAMASE INHIBITOR; CEFOTAXIME; CEFTAZIDIME; CEFUROXIME; CEPHALOSPORIN; CIPROFLOXACIN; GENTAMICIN; PENICILLIN G; PIPERACILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TAZOBACTAM; TEICOPLANIN; VANCOMYCIN;

AIRWAY; ANTIBIOTIC THERAPY; ARTIFICIAL VENTILATION; ASPIRATION; BACTERIAL COLONIZATION; CLINICAL TRIAL; CRITICAL ILLNESS; DIAGNOSTIC PROCEDURE; DIGESTIVE SYSTEM; DRAIN; DRUG EFFICACY; DRUG MEGADOSE; EMPIRICISM; GLOTTIS; HOST RESISTANCE; HUMAN; HUMIDIFIER; INFECTION CONTROL; KINETICS; PATHOGENESIS; PATIENT POSITIONING; PHYSIOTHERAPY; PNEUMONIA; PROPHYLAXIS; RECUMBENCY; RESPIRATORY SYSTEM; REVIEW; RISK FACTOR; SECRETION; STRESS ULCER; TREATMENT OUTCOME; VENTILATOR;

EID: 0041430869     PISSN: 13000144     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Lode H, Shaberg T, Raffenberg M, et al. Nosocomial pneumonia in the Critical Care Unit. Infections in Critical Care. In: B.A. Cunha. Critical Care Clinics 14: 119-133, 1998.
2. Cook D. Ventilator associated pneumonia: perspectives on the burden of illness. Intensive Care Med 26 Suppl 1:S31-S37, 2000.
3. Bauer TT, Ferrer R, Angrill J, et al. Ventilator-associated pneumonia: incidence, risk factors, and microbiology. Semin Respir Infect 15: 272-279, 2000.
4. Cook DJ, Walter SD, Cook RJ, et al. Incidence and risk factors for ventilator-associated pneumonia in critically ill patients. Ann Intern Med 129: 433-440, 1998.
5. Cook DJ. Kollef MH. Risk factors for ICU-acquired pneumonia. JAMA 279: 1605-1606, 1998.
6. Bonten MJ. Controversies on diagnosis and prevention of ventilator-associated pneumonia. Diagn Microbiol Infect Dis 34: 199-204, 1999.
7. Smulders K, van der Hoeven H, Weers-Pothoff I, et al. A randomized clinical trial of intermittent subglottic secretion drainage in patients receiving mechanical ventilation. Chest 121: 858-862, 2002.
8. Shorr AF, O'Malley PG. Continuous subglottic suctioning for the prevention of ventilator-associated pneumonia: potential economic implications. Chest 119: 228-235. 2001.
9. Wood GC. Boucher BA, Croce MA, et al. Aerosolized ceftazidime for prevention of ventilator-associated pneumonia and drug effects on the proinflammatory response in critically ill trauma patients. Pharmacotherapy 22: 972-982, 2002.
10. Adair CG, Gorman SP, Byers LM, et al. Eradication of endotracheal tube biofilm by nebulised gentamicin. Intensive Care Med 28: 426-431, 2002.
11. Pneumatikos I, Koulouras V. Nathanail C, et al. Selective decontamination of subglottic area in mechanically ventilated patients with multiple trauma. 20: Intensive Care Med 28: 432-437, 2002.
12. Vincent JL, Lobo S, Struelens M. Ventilator associated pneumonia: risk factors and preventive measures. J Chemother 1: 211-217, 2001.
13. Ntoumenopoulos G, Presneill JJ, McElholum M, et al. Chest physiotherapy for the prevention of ventilator-associated pneumonia. Intensive Care Med 28: 850-856, 2002.
14. Combes P, Fauvage B, Oleyer C. Nosocomial pneumonia in mechanically ventilated patients, a prospective randomised evaluation of the Stericath closed suctioning system. Intensive Care Med 26: 878-882, 2000.
15. Livingston DH. Prevention of ventilator-associated pneumonia. Am J Surg 179 (2 Suppl 1): 12-17, 2000.
16. Bonten MJ, Bergmans DC, Hoepelman IM, Stobberingh EE. Ventilator-associated pneumonia; controversies with respect to diagnosis, pathogenesis, therapy and prevention. Ned Tijdschr Geneeskd 143: 726-730, 1999.
17. Yildizdas D, Yapicioglu H, Yilmaz HL. Occurrence of ventilator-associated pneumonia in mechanically ventilated pediatric intensive care patients during stress ulcer prophylaxis with sucralfate. ranitidine, and omeprazole. J Crit Care 17: 240-245. 2002.
18. Girou E, Schortgen F, Delclaux, C, et al. Association of noninvasive ventilation with nosocomial infections and survival in critically ill patients. JAMA 284: 2361-2367, 2000.
19. Carlucci A, Richard J-C, Wysocki M, et al. Noninvasive versus conventional mechanical ventilation: an epidemiologic survey. Am J Respir Crit Care Med 163: 874-880, 2001.
20. Dupont H. Mentec H, Sollet JP, et al. Impact of appropriateness of initial antibiotic therapy on the outcome of ventilator-associated pneumonia, intensive Care Med 27: 355-362, 2001.
21. Kollef M, Sherman G, Ward S, et al. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 115: 462-474, 1999.
22. Singh N, Rogers P, Atwood CW, et al. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit: a proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med 162: 505-511, 2000.
23. Fowler A, Flavin K, Barr J, et al. Variability in Antibiotic Prescribing Patterns and Outcomes in Patients with Clinically Suspected Ventilator-Associated Pneumonia .........
24. Lynch JP. Hospital-acquired pneumonia: risk factors, microbiology. and treatment. Chest 119: 373S-384S, 2001.
25. Alvarez-Lerma F, Insausti-Ordenana J, Jorda-Marcos R. et al. Efficacy and tolerability of piperacillin-tazobactam vs. ceftazidime in association with amikacin for treating nosocomial pneumonia in intensive care patients: a prospective randomized multicenter trial. Intensive Care Med 27: 493-502. 2001.
26. Joshi M, Bernstein J, Solomkin J, et al. Piperacillin/tazobactam plus tobramycin vs. ceftazidime plus tobramycin for the treatment of patients with nosocomial lower respiratory tract infection: Piperacillin/Tazobactam Nosocomial Pneumonia Study Group. J Antimicrob Chemother 43: 389-397, 1999.
27. American Thoracic Society. Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies. Am J Respir Crit Care Med 153:1711-1725, 1996.
28. Fagon JY, Chastre J, Wolff M, et al. Invasive and non-invasive strategies for management of suspected ventilator-associated pneumonia: a randomized trial. Ann Intern Med 132: 621-630, 2000.
29. Wunderink RG. Therapy for nosocomial pneumonia. Curr Opin Pulm Med 3: 120-124, 1997.
30. Niederman MS. An approach to empiric therapy of nosocomial pneumonia. Med Clin North Am 78: 1123-1141, 1994.
31. Richards MJ, Edwards JR, Culver, DH, et al. Nosocomial infections in medical intensive care units in the United States. Crit Care Med 27: 887-892, 1999.
32. Kollef MH. Antimicrobial therapy of ventilator-associated pneumonia: how to select an appropriate drug regimen. Chest 115: 8-11, 1999.
33. Bowton DL. Nosocomial pneumonia in the ICU: year 2000 and beyond. Chest 115: 28S-33S, 1999.
34. Kashuba AD, Nafziger AN, Drusano GL, et al. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by Oram-negative bacteria. Antimicrob Agents Chemother 43: 623-629, 1999.
35. Sanchez-Nieto JM, Torres A, OarciaCordoba F, et al. Impact of invasive and noninvasive quantitative culture sampling on outcome of ventilatorassociated pneumonia: a pilot study [published erratum in Am J Respir Crit Care Med 157:1005, 1998]. Am J Respir Crit Care Med 157: 371-376, 1998.
36. Yates RR. New intervention strategies for reducing antibiotic resistance. Chest 115: 24S-27S, 1999.
37. Kollef MH, Vlasnik J, Sharpless L, et al. Scheduled change of antibiotic classes: a strategy to decrease the incidence of ventilator-associated pneumonia. Am J Respir Crit Care Med 156: 1040-1048, 1997.
38. Dominguez EA, Smith TL, Reed E, et al. A pilot study of antibiotic cycling in a hematology-oncology unit. Infect Control Hosp Epidemiol 21: S4-S8, 2000.
39. Rello J, Ausina V, Ricart M, et al. Impact of previous antimicrobial therapy on the etiology and outcome of ventilator-associated pneumonia. Chest 104: 1230-1235, 1993.